Wuhan Youziyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bisspecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer and senile eye diseases to address medical needs in the field of oncology and geriatric ophthalmology。
Prophylactic vaccine is one of the important research and development areas of Yuzhi Youji Biotechnology。Vaccines are targeted at pathogens or proteins (polypeptides, peptides), polysaccharides or nucleic acids that are essential for pathogen infection, and can induce specific humoral and/or cellular immunity after immunization with one or more components, directly or through carriers, so that the body can obtain immunity against the disease。The current use of vaccines has evolved from preventing disease to treating it,There are preventive vaccines and therapeutic vaccines: preventive vaccines are the combination of pathogenic microorganisms (such as bacteria, viruses, etc.) and their metabolites,An autoimmune agent prepared by artificially attenuated, inactivated, or transgenic methods for the prevention of infectious diseases,Such vaccines retain the immunogenic properties of the pathogen to induce a moderate immune response against disease infection;Therapeutic vaccines are used in an organism that is already infected with pathogenic microorganisms or already suffering from certain diseases,By inducing a specific immune response,Products or articles of natural, synthetic, or recombinant gene expression designed to treat or prevent disease progression。At present, there are five major technical routes for vaccines against novel coronavirus in the world: inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine, and nucleic acid vaccine。Y2019,It is Youzhiyou Bio that has responded aggressively during the COVID-19 pandemic,A novel recombinant SARS-CoV-2 subunit protein vaccine developed in cooperation with Wuhan Institute of Virology,Phase Ia clinical trials have been completed,And obtained Ethics Committee approval to initiate the Phase IIa clinical trial of Y2019 in China。
The company has advanced platform technology and strong research and development capabilities, and is in a leading position in the discovery and development of drug candidates for the treatment of cancer and aging degenerative diseases。Strategically developed four innovative platforms, including YBODY®, Check-BODY and Nano-YBODYTMThree dual resistant platforms and UVAX®Vaccine platform。
The company has designed and developed ten drug candidate pipelines, five of which are in clinical development in China and another five in development and preclinical stages。The company strategically selects potential targets for our drug candidates and focuses on therapeutic areas where only a few practitioners have the expertise and resources and have excellent market potential。